Ocular Therapeutix Q2 2024 GAAP EPS $(0.26) Misses $(0.22) Estimate, Sales $16.441M Beat $15.824M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix reported its Q2 2024 financial results with a GAAP EPS of $(0.26), missing the estimate of $(0.22). However, the company reported sales of $16.441 million, beating the estimate of $15.824 million.
August 07, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ocular Therapeutix reported mixed Q2 2024 results with a GAAP EPS of $(0.26), missing the estimate of $(0.22), but sales of $16.441 million beat the estimate of $15.824 million.
The mixed earnings report, with a miss on EPS but a beat on sales, is likely to result in a neutral short-term impact on OCUL's stock price. Investors may weigh the negative EPS against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100